Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited.
COVID-19
/ prevention & control
COVID-19 Vaccines
Health Care Rationing
/ organization & administration
Hematologic Neoplasms
/ complications
Humans
Immunity
Immunization Programs
/ organization & administration
Odds Ratio
Proportional Hazards Models
Public Health
/ methods
Risk
Risk Factors
Treatment Outcome
Vaccination
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
pubmed:
24
12
2020
medline:
17
2
2021
entrez:
23
12
2020
Statut:
ppublish
Résumé
Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.
Identifiants
pubmed: 33355178
pii: 2159-8290.CD-20-1817
doi: 10.1158/2159-8290.CD-20-1817
pmc: PMC8053003
mid: NIHMS1691478
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-236Subventions
Organisme : NCI NIH HHS
ID : P01 CA244118
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197633
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Cancer Discov. 2020 Jul 31;:
pubmed: 32737082
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
J Clin Oncol. 2020 Nov 20;38(33):3914-3924
pubmed: 32986528
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
J Natl Cancer Inst. 2021 Jun 1;113(6):691-698
pubmed: 33031532
J Clin Oncol. 2020 Oct 20;38(30):3538-3546
pubmed: 32795225
Nat Med. 2020 Aug;26(8):1218-1223
pubmed: 32581323
J Natl Cancer Inst. 2021 Apr 6;113(4):371-380
pubmed: 33136163
Ann Hematol. 2021 Feb;100(2):383-393
pubmed: 33159569
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Blood Rev. 2021 May;47:100775
pubmed: 33187811
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
MMWR Morb Mortal Wkly Rep. 2020 Dec 11;69(49):1857-1859
pubmed: 33301429
Cancer Discov. 2020 Oct;10(10):1514-1527
pubmed: 32699031
Cancer. 2020 Oct 1;126(19):4294-4303
pubmed: 32729142
Cancer. 2021 Jan 15;127(2):266-274
pubmed: 33112411
Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
J Hematol Oncol. 2020 Jun 10;13(1):75
pubmed: 32522278
Cancer. 2020 Dec 1;126(23):5069-5076
pubmed: 32910456
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Cancer Discov. 2020 Aug;10(8):1121-1128
pubmed: 32398243
Front Oncol. 2020 Jul 22;10:1279
pubmed: 32903324
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
JCO Glob Oncol. 2020 Apr;6:557-559
pubmed: 32250659
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
Ann Oncol. 2020 Aug;31(8):1088-1089
pubmed: 32330541
Front Oncol. 2020 Nov 20;10:595804
pubmed: 33330085